Moment of Truth for Acomplia in U.S.

The next week ahead will be the moments of truth for Acomplia in United States.

First time the long awaited, the FDA staff will disclose his views about diet drug rimonabant (Acomplia / Zimulti) on June 12, 2007.

The next day on June 13, 2007 Endocrinologic and Metabolic Drug Advisory Committee , a panel of outside experts will reveal the various concerns about Acomplia and its side effects.The committee will also vote on recommendation of FDA approval.

The recommendations of advisory committees are not followed by the FDA for the approval of the diet drug acomplia. The staff report and the advisory panel vote gives a significance regarding the decision of FDA.

The best case for the acomplia is it could be on the market by early fall while the wrost case could be more trial asked by FDA .

Sanofi-Aventis has constantly concern over rimonabant's side effects. It has said that the data of side effects will be presented to experts .